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Abstract
Background: Fas and FasL is important mediators of apoptosis. We have previously reported that
the stress levels of corticosterone (CORT, glucocorticoid in rat) increase expression of Fas/FasL
and activate Fas/FasL signal pathway in rat Leydig cells, which consequently leads to apoptosis.
Moreover, our another study showed that nuclear factor of activated T-cells (NFAT) may play a
potential role in up-regulation of FasL during CORT-treated rat Leydig cell. It is not clear yet how
NFAT is involved in CORT-induced up-regulation of FasL. The aim of the present study is to
investigate the molecular mechanisms of NFAT-mediated FasL expression in CORT-treated Leydig
cells.
Results: Western blot analysis showed that NFAT2 expression is present in mouse Leydig tumor
cell (mLTC-1). CORT-induced increase in FasL expression in mLTC-1 was ascertained by Western
Blot analysis and CORT-induced increase in apoptotic frequency of mLTC-1 cells was detected by
FACS with annexin-V labeling. Confocal imaging of NFAT2-GFP in mLTC-1 showed that high level
of CORT stimulated NFAT translocation from the cytoplasm to the nucleus. RNA interference-
mediated knockdown of NFAT2 significantly attenuated CORT-induced up-regulation of FasL
expression in mLTC. These results corroborated our previous finding that NFAT2 is involved in
CORT-induced FasL expression in rat Leydig cells and showed that mLTC-1 is a suitable model for
investigating the mechanism of CORT-induced FasL expression. The analysis of reporter constructs
revealed that the sequence between -201 and +71 of mouse FasL gene is essential for CORT-
induced FasL expression. The mutation analysis demonstrated that CORT-induced FasL expression
is mediated via an NFAT binding element located in the -201 to +71 region. Co-transfection studies
with an NFAT2 expression vector and reporter construct containing -201 to +71 region of FasL
gene showed that NFAT2 confer a strong inducible activity to the FasL promoter at its regulatory
region. In addition, chromatin immunoprecipitation assay further confirmed the results of reporter
gene studies by showing the specific binding of NFAT2 to the -201 to +71 region.
Conclusion: In the present study, we demonstrated that NFAT2 directly stimulates transcription
of FasL in high level CORT-treated mLTC-1. In conclusion, the present study provides further
evidence for our finding that CORT-induced FasL expression in Leydig cells is mediated by NFAT.
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Background
Fas and its ligand FasL are a pair of trans-membrane pro-
teins critically involved in apoptosis. Fas is expressed in
many types of tissues, whereas FasL expression is more
restricted [1]. FasL expression is predominantly found in
activated T cells. However, its expression is also reported
in and outside of the immune system, such as NK cells,
macrophages and Sertoli cells in testis [2-6].
In male mammalian, the sexual hormone testosterone is
secreted by Leydig cells in testis. We have recently demon-
strated that the high levels of corticosterone (CORT, glu-
cocorticoid in rat) that are typically achieved during stress
induce apoptotic death of Leydig cells and the activation
of the Fas/FasL system, cleavage of procaspase-3, loss of
mitochondrial membrane potential and increased ROS
generation are all implicated in the process of CORT-
induced Leydig cell death [7-9]. But the mechanism of
FasL expression regulation in CORT-mediated Leydig cell
apoptosis is unclear. Transcriptional regulation of FasL
expression is a complicated process, which could be
involved in a variety of transcriptional factors [10]. It was
known that FasL expression is dependent on nuclear fac-
tor of activated T-cells (NFAT) in T lymphocyte. In our
another study, it was found that the expression of FasL
was increased in 100 nM CORT-treated rat Leydig cells
and the increased expression could be alleviated by NFAT
inhibitor CsA. Meanwhile, Western blot analysis of NFAT
protein in the cytoplasm and nuclei demonstrated that
NFAT was activated by CORT treatment [11]. These results
indicated that NFAT is involved in CORT-induced FasL
expression in Leydig cells, but the molecular basis for this
process is not clear yet. Therefore, the present study is ded-
icated to investigate how NFAT be involved in regulation
of FasL transcription.
Results
Analysis of NFAT2 expression in Leydig cells
To observe whether NFAT is expressed in Leydig cells,
NFAT mRNA and protein expression in Leydig cells was
assessed using RT-PCR and Western Blotting respectively.
As shown in Fig. 1A, a band corresponding to NFAT
mRNA was observed. Fig 1.B shows that a 100 kDa band
corresponding to NFAT was identified by anti-NFAT anti-
body.
Assay of FasL expression in mLTC-1 cells
For assay of FasL mRNA in mLTC-1 cells, a total RNA were
extracted from the cells. A signigicantly increased level of
FasL mRNA was found in mLTC-1 cells treated with CORT
(Fig. 2.A). To further assay the product of FasL expression
in mLTC-1 cells subjected to 100 nM CORT treatment, the
lysates from mLTC-1 cells were examined by Western blot-
ting. As predicted, immunoblotting with anti-FasL anti-
body revealed the expression of a band with a M.W about
40 kDa (Fig 2.B). Taken together, these results indicate
that CORT increase expression of FasL in mLTC-1 cells. To
analyze the effect of CsA in CORT-induced FasL expres-
sion. mLTC-1 cells were treated with 100 nM CORT and
100 ng/ml CsA for 12 h followed by detection of FasL
mRNA with RT-PCR and FasL protein with immunoblot-
ting. As shown in Fig. 2A, B, the addition of CsA alleviated
CORT-induced up-regulation of FasL expression.
RNA interference-mediated silencing of NFAT2 gene
The RT-PCR and Western blotting were used to evaluate
the efficiency of siRNA on NFAT2 expression. After trans-
fection of mLTC-1 cells with siRNA targeted to NFAT2,
expression of NFAT2 is specifically abrogated compared
with the control siRNA (Fig. 3A, B). To determine whether
Expression of NFAT2 in Leydig cells Figure 1
Expression of NFAT2 in Leydig cells. A. NFAT2 was 
determined by RT-PCR using specific primers. β-actin was 
used as a control to monitor RNA quality. Lane 1 is the 
marker. The DNA was visualized under UV immediately after 
staining with ethidium bromide. B. Western blotting was 
used to determine the expression of NFAT2 protein in Ley-
dig cells. Lane 1. The lysates from primary rat Leydig cells; 
Lane 2. The lysates extracted from T cells as a positive con-
trol; Lane 3. The lysates from mLTC-1 cells. β-actin was used 
as a control to monitor protein quality. The proteins were 
resolved by SDS-PAGE and immunoblotted with anti-
NFAT2. Strong bands of NFAT2 protein in mLTC-1 and pri-
mary rat Leydig cells can be seen, which is similar to that in T 
cells.BMC Cell Biology 2008, 9:31 http://www.biomedcentral.com/1471-2121/9/31
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NFAT2 is responsible for FasL expression in mLTC-1 cells,
FasL expression were also detected by RT-PCR and West-
ern blotting. As shown in Fig. 3C, D, FasL expression is
decreased in siRNA-transfected mLTC-1 cells, whereas
control siRNA-transfected cells were not affected.
CORT-induced NFAT2-GFP nuclear translocation
To determine whether CORT induces nuclear transloca-
tion of NFAT2, plasmids expressing a NFAT2-GFP fusion
protein were transfected into mLTC-1 followed by CORT
or CORT plus CsA treatment. As shown in Fig. 4, NFAT2-
GFP was distributed evenly throughout the cytoplasm in
Control cells. After CORT treatment, NFAT2-GFP translo-
cate to the nucleus, which was blocked by NFAT inhibitor
CsA. These results suggest that high level of CORT induces
nuclear translocation of NFAT in mLTC.
Enhancement of FasL promoter activity by CORT 
treatment
To determine whether CORT regulates FasL promoter
activity, FasL-P689 reporter construct was used to tran-
siently transfect mLTC-1 cells. Fig. 5A shows schematically
the -618 to +71 bp 5' regulatory region of FasL promoter
(FasL689) and the -618 to +71 bp FasL luciferase construct
(FasL-P689). As shown in Fig. 5B, CORT induced a 6-fold
increase in luciferase activity over untreated cells. This
result suggests that CORT treatment enhanced FasL tran-
Suppression of NFAT2 expression by siRNA attenuates  CORT-induced expression of FasL Figure 3
Suppression of NFAT2 expression by siRNA attenu-
ates CORT-induced expression of FasL. A. After cells 
were transfected with the siRNA, NFAT2 siRNA394 or 
NFAT2 siRNA1232, targeting NFAT2 gene for 48 h, the 
expression of NFAT2 mRNA was analyzed by RT-PCR with 
primers specific to NFAT2. The cells transfected with scram-
bled siRNA served as negative control, and beta-actin mRNA 
served as internal controls. Lane1. 100-bp marker; Lane 2. 
Scrambled siRNA; Lane3. NFAT2 siRNA394; Lane 4. NFAT2 
siRNA1232. B. Cells were transfected with the scrambled 
siRNA or siRNA targeting NFAT2 gene for 72 h, and expres-
sion of NFAT2 protein was analyzed by Western blotting 
with specific antibody. Lane1. Scrambled siRNA; Lane 2. 
NFAT2 siRNA394; Lane 3. NFAT2 siRNA1232. C. Expres-
sion of FasL mRNA was determined by RT-PCR in wild 
mLTC-1 (a) and mLTC-1 transfected with NFAT2 siRNA394 
(b) after cells were treated with CORT or CORT plus CsA. 
Lane 1. Marker; Lane 2, 3 and 4 is without CORT treatment, 
with CORT treatment and CORT plus CsA treatment, 
respectively. D. Expression of FasL protein was determined 
by Western blotting in wild mLTC-1 (a) and mLTC-1 trans-
fected with NFAT2 siRNA394 (b) after cells were treated 
with CORT or CORT plus CsA. Lane 1, 2 and 3 is without 
CORT treatment, with CORT treatment and CORT plus 
CsA treatment, respectively.
The enhancement of FasL mRNA and protein expression in  CORT-treated mLTC-1 cells Figure 2
The enhancement of FasL mRNA and protein 
expression in CORT-treated mLTC-1 cells. A. Expres-
sion of FasL mRNA was determined by RT-PCR in mLTC-1 
cells. Band intensity was normalized to the β-actin product 
generated using specific primers to β-actin. Lane 1. Marker; 
Lane 2. The level of FasL mRNA in mLTC-1 cells untreated 
with CORT; Lane 3. The level of FasL mRNA in mLTC-1 
cells treated with 100 nM CORT for 12 h; Lane 4. The level 
of FasL mRNA in mLTC-1 cells treated with 100 nM CORT 
plus 100 ng/ml CsA for 12 h. The level of FasL mRNA was 
increased following the CORT treatment. The mRNA level 
was decreased in mLTC-1 cells with CORT and CsA treat-
ment. B. Expression of FasL protein in mLTC-1 cells was 
determined by Western blot. Lane 1, 2, 3 is without CORT 
treatment, with CORT treatment and CORT plus CsA, 
respectively. The expression of FasL was increased with 
CORT treatment and decreased with CORT plus CsA treat-
ment.BMC Cell Biology 2008, 9:31 http://www.biomedcentral.com/1471-2121/9/31
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scriptional activity in mLTC-1 cells. These data show that
the -618- +71 region is sufficient for CORT-mediated acti-
vation of FasL expression.
Transfection of mLTC-1 cells with deletion constructs of 
FasL promoter
To localize the promoter regions responsive to CORT-
induced FasL expression and define the minimal func-
tional region, a detailed 5' deletion analysis of -618 to +71
bp region was undertaken with FasL-P689, FasL-P329,
FasL-P272, FasL-P238, FasL-P209, FasL-P138. These con-
structs were transiently transfected into mLTC-1 cells fol-
lowed by 100 nM CORT treatment. As shown in Fig. 6, a
significantly increased luciferase activity was presence in
FasL-P689, FasL-P329 and FasL-P272. FasL-P272 showed
the maximal promoter activity and minimal 5' regulation
region among these constructs. These data suggest that the
272 bp sequence might be the regulatory elements that
respond to CORT-induced signaling and served as a basis
for mutational analysis.
Transfection of mLTC-1 cells with mutant FasL promoter 
constructs at 272 bp sequence
Figure 6 shows that there are two NFAT site in the 272 bp
sequence. The transcription activity of FasL-P272 is several
times higher than that of FasL-P238. We infer that the dis-
tal NFAT site is more important than the proximal NFAT
site. To further determine the function of NFAT at 272 bp
sequence, the mutant FasL-P272 constructs (FasL-
P272m), in which a mutation was introduced at the distal
NFAT site, was used in transient tranfection assays. It was
observed that up to 80% of luciferase activity indicating
FasL promoter activity was lost after the mutant construct
was transiently transfected into mLTC-1 cells followed by
100 nM CORT treatment. mLTC-1 cells were transfected
with the FasL-P272m (Fig. 7). This observation indicates
that the GGCGGAAA sequence (NFAT binding site) is the
critical site for FasL promoter activity in CORT-treated
mLTC-1 cells.
Activation of FasL promoter activity with transfection of 
NFAT expression construct
To further establish that whether the NFAT directly acti-
vates FasL promoter, cotransfection with the NFAT expres-
sion vector pcDNA3.1-NFAT and FasL-P272 were
conducted in mLTC-1 cells. pcDNA3.1-NFAT is under the
control of pcDNA3.1. pcDNA3.1-NFAT with FasL-P272
induced potent promoter activity. However, co-transfec-
tion of pcDNA3.1-NFAT with FasL-P272m induced little
promoter activity (Fig. 8). The data indicate that NFAT is
capable of binding to the GGAAA site of the FasL-P272
promoter construct.
The enhancement of transcriptional activity of FasL pro- moter in CORT- treated mLTC-1 cells Figure 5
The enhancement of transcriptional activity of FasL 
promoter in CORT- treated mLTC-1 cells. A. Sche-
matic representations of known transcription factor binding 
sites in the 5' regulatory region of the FasL gene and 
reporter-luciferase constructs used in these studies. Lengths 
of the promoter regions in the 5' truncation constructs are 
relative to the transcription start site. B. Analysis of tran-
scriptional activity of FasL promoter in mLTC-1 cells sub-
jected to CORT treatment. mLTC-1 cells were transiently 
transfected with luciferase reporter constructs containing 
the -618 to +71 bp region of FasL promoter (FasL-P689). 
The transfected cells were treated with vehicle as control or 
treated with 100 nM CORT for 12 h. The luciferase activity, 
normalized to an internal Renilla control, was compared with 
the activity of the transfected but no treated cells. There 
data are representative of at least three independent experi-
ments. ** denotes a significant difference compared with 
control at P < 0.01.
CORT-induced nuclear translocation of NFAT2 in mLTC-1  cells Figure 4
CORT-induced nuclear translocation of NFAT2 in 
mLTC-1 cells. mLTC-1 cells were transiently transfected 
with NFAT2-GFP expressing vector. 36 h after transfection, 
cells were treated with 100 nM CORT or 100 nM CORT 
plus 100 ng/ml CsA for 12 h. The cells were rinsed with PBS 
and fixed. Representative fields of cells were viewed by Con-
focal microscopy and photographed.BMC Cell Biology 2008, 9:31 http://www.biomedcentral.com/1471-2121/9/31
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Specific Binding of NFAT2 to the FasL promoter in vivo
Chromatin immunoprecipitation (ChIP) assay was
employed to assess the specific binding of NFAT to the tar-
get site in promoter region of the FasL gene in vivo (Fig.
9). A five-fold enrichment for FasL promoter DNA over
DNA immunoprecipitated with a nonspecific immu-
noglobulin G (IgG) control antibody was demonstrated.
This result indicates that NFAT bind directly to the FasL
promoter region.
Detection of CORT-induced apoptosis of mLTC-1 cells
To verify whether 100 nM CORT which induces up-regu-
lation of FasL in mLTC-1 could induce apoptosis, PI and
Annexin V-labeled FACS assay were performed (Fig. 10).
CORT treatment resulted in a significant increase of apop-
totic frequency of mLTC-1 cells, and CsA, the specific
inhibitor of NFAT, alleviated the increase of apoptosis.
Discussion
The receptor-ligand pair of Fas and FasL mediates apopto-
sis in a wide variety of different cell populations. The
importance of these interactions has been convincingly
demonstrated in murine and humans possessing loss of
function mutations in either molecule [15-18]. The bio-
logical importance of FasL has been highlighted recently
by work demonstrating its critical role in both activation-
induced cell death in T cells and in the maintenance of
immune privilege within certain tissues [19-21]. How-
ever, relatively little is known about factors that regulate
inducible expression of FasL outside of the immune sys-
tem. Our previous studies established a critical role for
FasL in Leydig cell via its action in CORT-induced apopto-
sis. We are the first to demonstrate that involvement of
NFAT on regulation of FasL expression in CORT-induced
Leydig cell apoptosis [11]. But the molecular mechanisms
of NFAT-mediated up-regulation of FasL expression in
Transient transfection of mLTC-1 cells with mutant con- struct of the FasL promoter Figure 7
Transient transfection of mLTC-1 cells with mutant 
construct of the FasL promoter. Cultured mLTC-1 cells 
transfected with FasL-P272 or FasL-P272m were treated 
with 100 nM CORT for 12 h followed by luciferase activity 
assays. The transfected cells which were treated with vehicle 
served as controls. The mLTC-1 cells with CORT treatment 
dramatically increased transcriptional activity of FasL-P272, 
but not FasL-P272m. Up to 80% of the FasL promoter activ-
ity was lost in mLTC-1 cells transfected with the FasL-P272m 
when the cells were incubated with 100 nM CORT, com-
pared with that in the cells transfected with FasL-P272. 
Asterisk indicates that the difference between FasL-P272 and 
FasL-P272m is statistically significant (P < 0.05).
Delineation of CORT-responsive cis-acting elements in the  FasL promoter Figure 6
Delineation of CORT-responsive cis-acting elements 
in the FasL promoter. A. Schematic representation of 
FasL 5' truncation reporter- luciferase constructs. B. A series 
of FasL-luciferase reporter constructs were transfected into 
mLTC-1 cells. After overnight incubation, the mLTC-1 cells 
were treated with 100 nM CORT for an other 12 h. The 
cells were lysed and assayed for luciferase activity. The luci-
ferase activity was compared with the normalized activity of 
the transfected but not treated cells. These data are repre-
sentative of at least three independent experiments and are 
normalized to an internal Renilla control. ** denote a signifi-
cant difference compared with control at P < 0.01. * denote a 
significant difference compared with control at P < 0.05.BMC Cell Biology 2008, 9:31 http://www.biomedcentral.com/1471-2121/9/31
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CORT-induced Leydig cell apoptosis are unknown. Regu-
lation of FasL expression is a complicated process, which
could be involved in a variety of trascriptional factors
including NFAT, SP1, early growth response gene (Egr)
and so on. The NFAT family of transcription factors is
composed of four family members NFAT1, NFAT2,
NFAT3 and NFAT4, and is best known for its role in the
regulation of the T cell immune response [22-27]. The
principal function of NFAT in T cells is to couple stimula-
tion of the T cell antigen receptor to changes in the expres-
sion of a number of cytokine and other immunologically
important genes. NFAT are regulated primarily at the level
of their subcellular localization through the actions of ser-
ine/threonine phosphatase calcineurin (CaN). In resting
cells, NFAT family members are normally located in the
cytoplasm in a hyperphosphorylated latent form. How-
ever, following activated CaN directly dephosphorylates
NFAT proteins, nuclear import and increased intrinsic
DNA binding activity occur, which could be specially
inhibited by CsA. Once located in the nucleus, NFAT are
then free to bind to their target promoter elements and
activate the transcription of specific NFAT target genes,
either alone or in combination with other nuclear part-
ners.
This aspect of NFAT regulation is likely to be significant,
since both the extent and duration of NFAT activity have
recently been shown to influence the qualitative pattern
of NFAT-dependent gene expression induced during T cell
activation [28]. The NFAT signaling pathway is certainly
best known for its role in the regulation of the immune
response. The NFAT is expressed in many cell types and
contributes to diverse cellular functions [22,29-34].
Therefore, it has become increasingly apparent that this
pathway also plays an important role in the regulation of
a wide variety of cellular responses in a number of other
tissues.
Our recent study had verified that NFAT was involved in
CORT-induced expression of FasL in rat Leydig cells [11].
Owing to relatively little is known about NFAT regulation
Recruitment of NFAT to the FasL promoter region Figure 9
Recruitment of NFAT to the FasL promoter region. 
ChIP analysis of the FasL promoter region was carried out on 
cells treated with CORT. The chromatin DNA selected by 
anti-NFAT antibody was amplified with FasL specific primers. 
Lane 1, marker; Lane 2, the input of mLTC-1 cells; Lane 3, 
the ChIP DNA from mLTC-1 cells untreated with CORT. 
Lane 4, the ChIP DNA from mLTC-1 cells treated with 100 
nM CORT; Lane 5, the ChIP DNA from mLTC-1 cells 
treated with 100 nM CORT and 100 mg/ml CsA; Lane 6, 
non-specific IgG; Lane7, non-specific primer.
Co-transfection of NFAT expression vector activates FasL  promoter Figure 8
Co-transfection of NFAT expression vector activates 
FasL promoter. A. Leydig cells were co-transfected with 
FasL-P272 (0.4 μg) and pcDNA3.1-NFAT (NFAT expression 
vector, 0.8 μg), or empty pcDNA3.1. Luciferase activity was 
determined after 48 h incubation with CORT. CORT treat-
ment significantly increased the luciferase activity compared 
with controls. The increase of Luciferase activity in the cells 
co-transfected with pcDNA3.1-NFAT and FasL-P272 is sev-
eral times higher than that in the cells cotransfected with 
pcDNA3.1 and FasL-P272. B. Leydig cells were co-trans-
fected with FasL-P272m (0.4 μg) and pcDNA3.1-NFAT (0.8 
μg), or empty pcDNA3.1. Luciferase activity was determined 
after 48 h incubation with CORT. CORT treatment did not 
induce elevation of luciferase activity in cells either trans-
fected with or without pcDNA3.1-NFAT. Results represent 
the average of three independent transfection experiments.BMC Cell Biology 2008, 9:31 http://www.biomedcentral.com/1471-2121/9/31
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of FasL expression outside of the immune system, no
doubt, it is very interesting to observe whether NFAT reg-
ulate FasL expression through affection FasL promotor
activation in CORT-treated Leydig cells.
In the present study, mLTC-1 were selected as cell model
due to its suitability for transfection. Although it is widely
accepted that mLTC-1 is a favorable model for study on
biology of Leydig cells, we validated firstly that CORT-
induced up-regulation of FasL expression is also present in
mLTC-1 by RT-PCR and Western blotting analysis. West-
ern blotting analysis showed NFAT2 is the predominant
isoform in mLTC. However, other members of NFAT fam-
ily, i. e. NFAT1, NFAT3 and NFAT4 exprssion is very low
compared to NFAT2 in mLTC-1 (our unpublished data).
It was also shown that NFAT2-GFP chimeric protein trans-
located from cytoplasm to nuclus after CORT treatment
and siRNA-mediated silencing of NFAT decreased the
extent of CORT-induced FasL expression. These results
were in accord with our finding in rat Leydig cells, i.e. high
level CORT activates Fas/FasL signal pathway through
activation of NFAT.
Previous studies from other investigators suggested the
presence of multiple elements at -689 bp at 5' untrans-
lated region of FasL promoter, which is capable of enhanc-
ing transcriptional activity of the FasL promoter in T cells
[35]. Furthermore, we predicated the transcription start
site and transcription factor binding sites on FasL pro-
moter by analyzing the sequence of FasL 5' untranslated
region through online-based computer program. Based
on these messages, the -689 bp at 5' untranslated region
of FasL promoter was selected as an object to observe
NFAT regulation of FasL promoter activity in present
study. In order to elucidate the mechanism of CORT-trig-
gered up-regulation of FasL expression in CORT-treated
Leydig cells, we cloned -689 bp (-618- +71) at 5' untrans-
lated region of FasL promoter and found that the -618-
+71 region is available and sufficient for further establish-
ment of mechanisms of NFAT-triggered FasL expression in
CORT-treated Leydig cells.
The data presented in this paper firstly suggested that
activity of FasL promoter (at -689 bp sequences) was
enhanced in CORT-treated mLTC. To establish the mini-
mal function region on FasL promoter which is interac-
tion with NFAT, we synthesized a series of 5' deletion
constructs and tested their transcriptional activities in
response to CORT treatment. It was firstly found the pres-
ence of a high active site situated between -201- +71 (Fig.
8). Our present data showed that there are two NFAT
binding sites between -201-+71 region (with total 272 bp)
and only one NFAT binding site between -167-+71 region
(with total 238 bp). The 272 bp showed the maximal acti-
vation in whole FasL promotor sequences. Latinis et al.
reported that the binding of NFAT to the GGAAA site on
FasL active core sequence is critical for triggering FasL pro-
moter activity [36]. So this specific short sequence was
selected as mutated site in present experiment. It was
found that the mutated sequence significantly resulted in
an inhibition of FasL promoter activity following the
nucleotides sequence was mutated. Finally, co-transfec-
tion experiments with the NFAT expression vector and
FasL promoter with report gene further showed that NFAT
enhanced transcriptional activity of FasL promoter by
interaction with its -272 bp DNA sequence, thereby regu-
Detection of CORT-induced apoptosis of mLTC-1 cells Figure 10
Detection of CORT-induced apoptosis of mLTC-1 
cells. A. mLTC-1 cells were incubated with either 100 nM 
CORT or 100 ng/mL CsA plus 100 nM CORT. The Leydig 
cells treated with a vehicle (Dimethyl Sulfoxide, DMSO) 
served as control. After 12-h incubation, the mLTC-1 cells 
were analyzed by FACS with annexin-V/PI double staining. 
The cells in the right lower quadrant were designated apop-
totic (propidium iodide (PI)-negative/annexin V-fluorescein 
isothiocyanate-positive), the cells in the left lower quadrant 
were designated alive (PI-negative/annexin V-FITC-negative), 
the cells in right upper quadrant were designated dead 
(PIpositive/annexin V-FITC-positive), and the cells in left 
upper quadrant were designated damaged (PI-positive/
annexin V-FITC-negative). B. The mLTC-1 cells treated with 
CORT showed increased frequencies of apoptotic labeling 
compared with the control. The Leydig cells treated with 
CORT plus CsA showed decreased frequencies of apoptotic 
labeling compared with the cells treated with CORT alone. * 
denote a significant difference compared with control at P < 
0.05. ** denote a significant difference compared with cells 
treated with CORT at P < 0.05.BMC Cell Biology 2008, 9:31 http://www.biomedcentral.com/1471-2121/9/31
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lating FasL promoter activity in CORT-treated Leydig cells.
In addition, mutation at -272 bp DNA sequence also
resulted in an inhibition of transcriptional activity of FasL
promoter in co-transfection experiments. Furthermore,
the ChIP result further confirms that NFAT directly bind
to FasL promoter sequence in vivo.
Conclusion
Our present findings provide further insight into the
mechanisms involved on the regulation of the FasL
expression in response to CORT treatment in Leydig cells.
In summary, the mechanisms of transcriptional regula-
tion of FasL expression in CORT-treated mLTC-1 is an
activation on transcription factor NFAT. The active tran-
scription factor interact with specific NFAT target genes in
FasL promoter sequence at -201 to +71 region, thereby
regulating FasL expression.
Methods
Cells and reagents
Cell line mLTC-1 (mouse Leydig tumor cell) was pur-
chased from American Type Culture Collection (Cat. No.
CRL-2065). CORT was purchased from Sigma Chemical
Co. QuickChange Site-Directed Mutagenesis Kit was pur-
chased from Stratagene Inc (La Jolla. CA, Cat.
No.200518). Qiagen Plasmid Maxiprep Kit was obtained
from Qiagen (Santa Clarita, CA, Cat. No.12162) The
Dual-Luciferase Reporter Assay System was purchased
from Promega Co (Madson, WI, Cat. No.E1910). The
Fluo-3/AM was purchased from Sigma Co. Specific anti-
body for FasL was obtained from Oncogene (Cambridge,
MA, Cat. No. PC78). The anti-NFAT2 was obstained from
Santa Cruz Biotechnology, Inc (Santa Cruz, CA, Cat. No.
SC-1149).
Isolation of primary rat Leydig cells
Adult Leydig cells were isolated from the 90-day-old rats
according to the procedure of Sriraman et al. [12], which
is a modification of the procedure described by Klinefelter
et al. [13]. The decapsulated testes were subjected to colla-
genase digestion in a 50 mL plastic tube containing 10 mL
medium with collagenase (600 units) and DNase (750
units). The tubes were placed in a shaking water bath and
constantly agitated (50 times/min) at 34°C for 15–20
min until the seminiferous tubules were separated. The
enzyme action was terminated by adding excess medium.
The tubules were allowed to settle by gravity and the
medium, consisting of interstitial cells, was aspirated and
filtered through a 100 μm nylon mesh. The filtrate was
centrifuged at 250 × g for 10 min at 25°C, which yielded
a crude interstitial pellet. The pellet obtained was sus-
pended in 35 mL 55% isotonic Percoll with 750 units
DNase in Oakridge tubes. The tubes were centrifuged at
20 000 × g for 1 h at 4°C. Percoll fractions corresponding
to densities of 1.070–1.090 g/mL were collected and the
cells present in this fraction were pelleted down by centrif-
ugation at 250 × g for 10 min at 25°C after diluting it with
3–4 volumes of the medium. The purities of the isolated
cell fractions were evaluated by histochemical staining for
3β-hydroxysteroid dehydrogenase activity, with 0.4 nm
etiocholanolone as the steroid substrate [14]. The enrich-
ment of the Leydig cells was up to a purity of 85% on aver-
age.
RNA isolation and RT-PCR
Total RNA was prepared from mLTC-1 cells using the Tri-
zol Reagent (Gibco, Cat. No.15596-026) according to the
manufacturer's instruction. First strand cDNA synthesis
was performed using Superscript II reverse transcriptase
(Invitrogen, Carlsbad, CA, Cat. No. A3500) in a reaction
using 2 μg of total RNA primed with random hexamers in
a total reaction volume of 20 μl. Following first strand
synthesis, 10% of the reaction volume was used as a DNA
template for amplification by polymerase chain reaction
(PCR). For detection of NFAT2, the forward and reverse
primers were 5'-GCCCTGACCACCGATAGCAC-3' and 5'-
GCTGCCTTCCGTCTCATAGTG-3', respectively. PCR was
performed for 30–32 cycles with denaturing at 94°C for 1
min, annealing at 58°C for 1 min and extension at 72°C
for 1 min, in a GeneAmp PCR System 9600 (PerkinElmer,
Norwalk, CT, USA). For detection of FasL, specific oligo-
nucleotide primers were used as follows: forward primers;
5'-ATTGGCACCATCTTTACT-3' and reverse primers; 5'-
CCTTAGAATCTGTTTGTCC-3'). PCR was performed for
28–30 cycles with denaturing at 95°C for 50s, annealing
at 58°C for 45s and extension at 72°C for 50s. The signal
intensities of the amplified fragments of NFAT2 and FasL
were normalized to β-actin using a densitometer. Ampli-
fied PCR products were separated by agarose gel electro-
phoresis and detected by ethidium bromide staining. For
amplification of NFAT2, the forward and reverse primers
were 5'- CCG GAA TTC GAC ATG ACG GGG CTG GAG
CAG GAC CCG GAG -3'and 5'- CGC GGA TCC TCG TAA
ATA AAA CAC CCT AGA AAG TTG AAA-3', respectively.
PCR was performed for 34 cycles with denaturing at 94°C
for 50s, annealing at 60°C for 45s and extension at 72°C
for 120s. The NFAT2 cDNA was purified by QIAquick PCR
Purification Kit.
Western blot analysis
mLTC-1 and primary rat Leydig cells were lysed in Ripa
buffer (1% NP-40, 0.1% SDS, 0.5% DOC, 150 mM NaCl,
10 mM Tris-HCl, and PMSF mixture) at 4°C for 30 min.
Protein concentrations were determined by the Bradford
dye-binding assay using bovine serum albumin as a stand-
ard. Aliquots of cell extracts containing equal amounts of
protein were separated by SDS-polyacrylamide gel electro-
phoresis on 8% gels using the Laemmli buffering system,
then proteins were transferred to Immuno-Blot polyvi-
nylidene difluoride membranes (Bio-Rad, Hercules, CA)BMC Cell Biology 2008, 9:31 http://www.biomedcentral.com/1471-2121/9/31
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and blocked by rocking for 1 h at room temperature in
blocking buffer (Tris-buffered saline with 0.1% Tween 20
and 5% nonfat dry milk). Blots were exposed to primary
antibodies for 1 h at room temperature, multiply washed
with Tris-buffered saline with 0.1% Tween 20 (TBST),
treated with secondary antibody (HRP-conjugated) for 1
h, and followed by a final series of washed with TBST. Pri-
mary (goat polyclonal anti-NFAT2 or rabbit polyclonal
anti-FasL) and secondary antibodies were prepared in
blocking buffer. Signals were detected with an Enhanced
Chemiluminescence kit (ECL Pierce, Rockford, IL) and
analyzed using Adobe Photoshop 6.0 software.
RNA interference
The following sequences specific for mouse NFAT2 gene
were used: NFAT2 siRNA394 (Sense: 5'-GGA GGU GGA
AGA CGU ACU UTT-3'; Antisense: 5'-AAG UAC GUC
UUC CAC CUC CTT-3') and NFAT2 siRNA1232 (Sense:
5'-CCG UCA CAU UCU GGU CCA UTT-3'; Antisense:
AUG GAC CAG AAU GUG ACG GTT-3'). The Lipo-
fectamine 2000 was used to deliver siRNA (100 pmol)
into cultured mLTC-1 cells (5 × 104) in 6-well plates
according to the manufacturer's protocol. The double-
strand scrambled siRNA (5'-UUC UCC GAA CGU GUC
ACG UTT-3') were used as negative control. The cultures
were incubated for six hours and then washed and incu-
bated in fresh medium. All siRNA were obtained from
Shanghai Genepharma Co. Inc. (Shanghai, China).
Plasmid constructions
Genomic DNA was isolated from C57BL6 using DNAeasy
kit (Qiagen, Valencia, CA, Cat. No.69504). A 689 bp PCR
fragment corresponding to the promoter region of FasL (-
618- +71) was generated using the upstream primer 5'-
CGGGGTACCGTACCTCAGTTTTCATCTGGTGACCA-
GAAG-3' and the downstream primer 5'-CCCAAGCTT-
GCACCCAGCCCCAGGAAA GG-3' in a PCR using
platinum Pfx high fidelity polymerase (Invitrogen,
Cat.No. 11708013) and 50 ng of genomic DNA template.
The resultant 689 bp fragment was gel-purified, and
cloned into pGEM ®-T Easy vector (Promega, Cat.No.
A1360) and sequenced for orientation and fidelity. This
plasmid (pGEM-689pCD95L) was served as the source of
the insert for further plasmid constructions. To make the
-618 to +71 luciferase reporter plasmid, the 689 bp insert
was excised with Kpn I and Hind III and ligated into the
Kpn I/Hind III site of pGL3 Basic luciferase vector
(Promega, Cat.No.E1751). To make the 5'truncation
mutants, shorter fragments were generated using new
upstream primers, and the common downstream primer
was used to make the -618 to +71 insert. For the -258 to
+71 fragment, the upstream primer 5'-CGGGGTAC-
CCAGGCAAGCCTGGTTTACCAGC C-3' and the common
downstream were used. To generate the -201 to +71 frag-
ment, the upstream primer 5'-CGGGGTACCCGAA-
GACTTGTCGTCAGAA ATTTC-3' was used. The -167 to
+71 fragment was produced using 5'-CGGGGTACCCTTC-
CTGGGGTT GCTGTGAGC- 3'. The -138 to +71 fragment
was produced using 5'-CGGGGTACCGCTTCTCAGCTTC
A ATGCAAG-3'. The -67 to +71 fragment was produced by
using the upstream primer 5' -CCCAAGCTT GCAC-
CCAGCCCCAGGAAAGG-3'. The resultant fragment were
subcloned into the polylinker site of pGEM-T vector and
sequenced for orientation and fidelity. Luciferase reporter
constructs were produced by excising the various frag-
ments with Kpn I and Hind III and then subcloning the
fragments into the polylinker site of pGL3-basic.
NFAT2 cDNA sequences were digested with EcoRI and
BamHI, and ligated into the EcoRI/BamHI site of pEGFP-
C1 plasmids to construct the NFAT2-GFP fusion protein
expression vector.
Site-directed mutagenesis
Mutant construct was generated by using the Quick-
Change Site-Directed Mutagenesis Kit. The mutation was
verified by DNA sequencing. Mutant of the NFAT site in
FasL promoter (FasL-P272m) were synthesized by Sangon
Co.: 5'-GTCGTCAGAAATTTCTGGGAATCAACTTCCT-
GGGGTTGCTGTGAG -3'.
Transient transfections and luciferase reporter assays
For transfection analysis, luciferase assays were performed
according to the manufacturer's instruction using the
Lipofectamine™ 2000 reagent (Invitrogen Co. Cat.
No.11668-019). Briefly, the cells were seeded into 24-well
plates at a density of 5 × 105 cells/well and incubated at
37°C overnight. Cells were then placed in DMEM with 10
% fetal bovine serum containing 1 μg of luciferase plas-
mid, 0.1 μg of pRL SV40 reporter plasmid, and 2 μg of
Lipofectamine™ 2000. Thirty-six hours following transfec-
tion, the cells were treated with 100 nM CORT. Following
the treatment, the Dual Luciferase Assay was performed by
lysing the cells in Passive Lysis Buffer, and reading the rel-
ative light units of one-fifth the lysate with both the firefly
substrate and the renilla substrate using a luminometer
(Monolight 2010, Analytical Luminescence Laboratory,
SanDiego, CA). Each transfection was performed in tripli-
cate and in a minimum of three independent experi-
ments.
Confocal microscopy analysis of NFAT2-GFP nuclear 
translocation
mLTC-1 were transiently transfected with NFAT2-GPF
expression vector. At 36 h after transfection, cells were
treated with 100 nM CORT, or 100 nM CORT plus 100
ng/ml CsA for 12 h. NFAT2-GFP expression and localiza-
tion was monitored by Confocal microscopy.BMC Cell Biology 2008, 9:31 http://www.biomedcentral.com/1471-2121/9/31
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Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was
performed according to the manufacturer's protocol.
mLTC, cultivated in DMEM containing 10% bovine calf
serum, were incubated with 100 nM CORT for 12 h, cross-
linked by formaldehyde for 10 minutes at 37°C. The reac-
tion was stopped with 0.125 M glycine. Cells were washed
using cold PBS containing protease inhibitors. DNA were
sheared by sonicate lysate to lengths between 200–1000
bp. Cell samples were centrifuged for 10 minutes at
13,000 rpm at 4°C and supernatant stored at -80°C as
chromatin extracts. For chip analysis, pre-cleared the sam-
ple with salmon sperm DNA/protein agarose for 30 min
at 4°C. Lysates were subjected to immunoprecipitation
with anti-NFAT2 antibodies (Santa Cruz Biotechnology)
and non-specific IgG (Santa Cruz) were added individu-
ally and incubated at 4°C overnight with rotation. Bound
and input chromatin samples were placed in 0.5% (wt/
vol) SDS and incubated at 65°C for 4 hours to reverse the
formaldehyde cross-linking. DNA was further purified by
phenol-chloroform extraction and ethanol precipitated
using glycogen as an inert carrier. Of the obtained DNA, 2
μl was used in a 20-μl PCR reaction (Taq DNA Polymer-
ase; Qiagen) using the following primers: FasL-F, 5'-
CAGTTAGCACAGAGACGCCAAT-3'; FasL-R, 5' -TGCT-
TCTCTGTGAGACACCCAC-3'.
Apoptosis assay
mLTC-1 cells were treated with 100 nM CORT or 100 nM
CORT plus 100 ng/ml CsA for 12 h followed by detection
of apoptosis. The annexin-V was used to assess apoptosis.
For the annexin-V assay, the mLTC-1 cells were incubated
with 10 μL propidium iodide (PI) and 5 μL FITC-annexin-
V (BD Biosciences, Franklin Lakes, NJ, USA) at room tem-
perature for 15 min. Then, the cells were analyzed on
FACS. Annexin-V binds to those cells that express phos-
photidylserine on the outer layer of the cell membrane,
and PI stains the cellular DNA of cells with a compro-
mised cell membrane. This allows for the discrimination
between live cells (unstained with either fluorochrome)
from apoptotic cells (stained only with annexin-V) and
necrotic cells (stained with both annexin-V and PI).
Statistics
All experiments were performed in triplicate. The Stu-
dent's t-test was used to determine the statistical signifi-
cance of the data obtained. P < 0.05 or P < 0.01 was taken
to represent a statistically significant difference between
group mean.
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